$LLY

Yuffa Ilya sold $2.9M of LLY

Yuffa Ilya (EVP&Pres, LLY USA&Global Capab) sold 2,500 shares of ELI LILLY & Co (LLY) at $1150.77 ($2.88M total) on 2026-06-10 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Yuffa Ilya
Published Jun 11, 2026, 8:23 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 11, 2026, 8:28 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$LLY
Neutral
high confidence
Mentioned
$LLY
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$LLYNeutralLow
01

Why it matters

Traders may monitor insider activity as a sentiment input, but 10b5-1 plans generally reduce the informational content versus discretionary sales.

02

Market read

A $2.88M LLY insider sale was disclosed, but it is pre-arranged under 10b5-1, limiting actionable fundamental implications.

03

What to watch

The article provides only the sale details; it does not state whether other insiders or large holders changed positions around the same time.

Relevance 5/10Novelty 6/10Timing: Filed June 11; sale executed June 10

Background

The article is a primary-source SEC Form 4 insider transaction disclosure (open-market sale) for LLY.

Company-level read

Ticker impact

$LLYNeutralHigh confidence
Context

SEC Form 4 shows EVP Yuffa Ilya sold 2,500 shares of LLY for about $2.88M on a pre-arranged 10b5-1 plan.

Expected impact

Low likelihood of sustained price impact; any reaction is likely muted and short-lived.

Evidence & confidence

The filing is an open-market sale under a pre-arranged 10b5-1 plan, with no accompanying fundamental or regulatory catalyst disclosed.

Market effects

No sector read-through; this is company-specific insider transaction data only.

None indicated.

None indicated.

Counterpoint

Even with 10b5-1, repeated insider selling can coincide with internal risk management or diversification, which some traders may still fade.

Key entities

  • ELI LILLY & Co

    Company whose shares were sold by an executive under a 10b5-1 plan.

  • Yuffa Ilya

    EVP & President, LLY USA & Global Capabilities; sold 2,500 shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$LLYLowAI 8/10

FDA approval for Lilly’s weekly insulin Onswik, shares dip

The FDA approved Eli Lilly's (LLY) once-weekly insulin Onswik for type 2 diabetes. The drug, already approved in the EU, Mexico, and Japan, aims to reduce injections from 365 to 52 per year. Despite the approval, LLY shares dipped 1.6%. Lilly's revenue and net income have surged, reaching $22.97bn and $7.1bn respectively in Q2 2026. The company faces competition from Novo Nordisk's Awiqli in the weekly insulin market.

$LLYHighAI 9/10

New once-weekly insulin injection for type 2 diabetes wins FDA approval

Eli Lilly's once-weekly insulin, Onswik, received FDA approval for type 2 diabetes. It reduces annual injections by over 300 compared to daily insulin. Trials with 3,400+ adults showed A1C declines similar to daily insulin glargine. Onswik will be available in the US in pre-filled pens. According to Lilly, it offers an alternative to daily injections.